Brickell Biotech Inc
F:VCC2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
K
|
Key Alliance Group Bhd
KLSE:KGROUP
|
MY |
|
Aoyama Zaisan Networks Co Ltd
TSE:8929
|
JP |
|
Cookpad Inc
TSE:2193
|
JP |
|
Alexander Marine Co Ltd
TWSE:8478
|
TW |
|
Gyldendal A/S
CSE:GYLD B
|
DK |
|
O
|
Osram Licht AG
XHAM:OSR
|
DE |
|
D
|
Dewhurst Group PLC
LSE:DWHA
|
UK |
|
FriendTimes Inc
HKEX:6820
|
CN |
|
Town Health International Medical Group Ltd
HKEX:3886
|
HK |
|
P
|
Puma SE
XHAM:PUM
|
DE |
|
V
|
Vanjia Corp
OTC:VNJA
|
US |
|
Washington Trust Bancorp Inc
NASDAQ:WASH
|
US |
|
Angi Inc
NASDAQ:ANGI
|
US |
|
M
|
Meshek Energy-Renewable Energies Ltd
TASE:MSKE
|
IL |
|
S
|
Sumasapo Inc
TSE:9342
|
JP |
|
Triller Group Inc
NASDAQ:ILLR
|
US |
|
Concejo AB (publ)
STO:CNCJO B
|
SE |
|
Seres Group Co Ltd
SSE:601127
|
CN |
|
T
|
TJX Companies Inc
BMV:TJX
|
US |
|
T
|
Teo Seng Capital Bhd
KLSE:TEOSENG
|
MY |
|
Gattaca PLC
LSE:GATC
|
UK |
|
Jianmin Pharmaceutical Group Co Ltd
SSE:600976
|
CN |
Brickell Biotech Inc
Total Current Liabilities
Brickell Biotech Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Brickell Biotech Inc
F:VCC2
|
Total Current Liabilities
$3.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Liabilities
$43.3B
|
CAGR 3-Years
14%
|
CAGR 5-Years
9%
|
CAGR 10-Years
15%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Liabilities
$11.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Liabilities
$25.5B
|
CAGR 3-Years
18%
|
CAGR 5-Years
17%
|
CAGR 10-Years
11%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Liabilities
$3.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
16%
|
CAGR 10-Years
23%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Liabilities
$4.4B
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
18%
|
|
Brickell Biotech Inc
Glance View
Brickell Biotech, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. The company is headquartered in Boulder, Colorado and currently employs 16 full-time employees. The Company’s pipeline combines several development-stage candidates and a cutting-edge platform with autoimmune and inflammatory disorders program for the treatment of primary axillary hyperhidrosis. Its products include Cialis, Taltz, Gemzar, Prozac, Cymbalta and Juvederm. Its lead development-stage program, BBI-02, is a Phase I ready, highly selective, and orally bioavailable DYRK1A inhibitor that has demonstrated in various preclinical models, including atopic dermatitis and rheumatoid arthritis. BBI-10, the Company’s lead early-stage STING inhibitor candidate, is a novel, potent, and orally available covalent STING inhibitor that specifically targets the palmitoylation site of STING, which allows to inhibit both wild-type STING and gain-of-function mutants.
See Also
What is Brickell Biotech Inc's Total Current Liabilities?
Total Current Liabilities
3.1m
USD
Based on the financial report for Dec 31, 2022, Brickell Biotech Inc's Total Current Liabilities amounts to 3.1m USD.
What is Brickell Biotech Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 1Y
-36%
Over the last year, the Total Current Liabilities growth was -36%.
